100 help plan
Gigabit: The chairman proposed to repurchase shares for 50 million yuan to 100 million yuan
Gigabit announced that the chairman proposed to repurchase shares for 50 million yuan to 100 million yuan.
Zuoli Pharmaceutical: The company's products are planned to be selected for the fourth batch of drugs in Fujian Province
According to the Fujian Provincial Medical Security Bureau on December 19, the fourth batch of Fujian Province Drug Centralized Procurement Announcement (No. 10) shows that the company's product Wuling Capsule intends to be selected for this centralized procurement.
West**: Proposed 10.7 billion yuan to acquire 100% equity of Hengsheng Beryllium
The western ** announced that the company intends to acquire 100% of the shares of Fuyun Hengsheng Beryllium Industry Co., Ltd. (hereinafter referred to as "Hengsheng Beryllium") held by Xinjiang Nonferrous Metals Industry (Group) Co., Ltd., and the transaction ** is 10.7 billion yuan. After the completion of the acquisition, the two parties will give full play to the synergies in smelting, technical equipment, procurement and sales, and operation management.
Shandong Publishing: The construction of the characteristic boutique publishing project and the printing equipment upgrading project has been completed
Shandong Publishing announced that the company's initial fund-raising investment project has completed the construction of the characteristic boutique publishing project and the printing equipment upgrading project, and has the conditions for completion, and now the above two projects will be completed, and the surplus funds raised after the completion of the characteristic boutique publishing project 32670,000 yuan and 5,992 surplus funds raised after the completion of the printing equipment upgrading project110,000 yuan, with a total savings of 6,024780,000 yuan for permanent replenishment of working capital.
Baoxin Software: The proposed capital increase does not exceed 19.7 billion yuan to hold Turing Robot].
Baoxin Software announced that it took the development of the domestic robot industry as an opportunity, and at the same time in order to strengthen the missing links in the company's own industrial chain, form an independent high-end industrial robot brand, break the monopoly of international brands on the high-end heavy-duty industrial robot market, and cut into the domestic alternative market of imported high-end robots. The board of directors of the company approved the cash capital increase not exceeding 19.7 billion yuan, holding Shanghai Turing Intelligent Robot Co., Ltd. *** referred to as "Turing Robot").
Huasen Pharmaceutical: Received the notice of approval for drug re-registration
Huasen Pharmaceutical announced that the company recently received the "Drug Re-registration Approval Notice" approved and issued by the Chongqing Municipal Food and Drug Administration on the company's product Pain Diarrhea Ning Granules.